India, Sept. 16 -- MAIA Biotechnology, Inc. (MAIA) has dosed the first U.S. patient in its ongoing Phase 2 THIO-101 clinical trial evaluating Ateganosine, the company's telomere-targeting lead candidate, in third-line non-small cell lung cancer.
The milestone follows FDA clearance of MAIA's amended investigational new drug submission, which highlights improved manufacturing capabilities and efficiencies supporting the program's expansion.
The U.S. portion of the Phase 2 expansion is funded by a $2.3 million grant from the National Institutes of Health, enabling MAIA to activate three clinical sites across the country to evaluate Ateganosine in patients who have progressed beyond standard checkpoint inhibitor therapy.
A Telomere-Targeting...